More Company News

Hutchison China MediTech

US$100m equity investment by General Atlantic
25 Jun 2020Read More

Hutchison China MediTech

Fruquintinib granted FDA Fast Track Designation for mCRC
18 Jun 2020Read More

Hutchison China MediTech

US$95m Guangzhou land compensation agreement
09 Jun 2020Read More

Hutchison China MediTech

Continuation of China Phase III FRUTIGA study of Fruquintinib in 2L gastric cancer
04 Jun 2020Read More

Hutchison China MediTech

Plans to submit US NDA for Surufatinib following FDA Pre-NDA meeting
01 Jun 2020Read More

Hutchison China MediTech

Savolitinib China NDA acceptance for NSCLC with MET ex14 skipping mutations
29 May 2020Read More

Hutchison China MediTech

Clinical Collaboration with Beigene
26 May 2020Read More

Hutchison China MediTech

Clinical data to be presented at ASCO 2020
14 May 2020Read More

Hutchison China MediTech

Surufatinib presentations at upcoming AACR virtual annual meetings
22 Apr 2020Read More

Hutchison China MediTech

Surufatinib granted FDA Fast Track Designations for NETs
17 Apr 2020Read More

1 2 3 4 … 6
Return to Hutchison China MediTech
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).